Preoperative cardiac risk stratification 2007: evolving evidence, evolving strategies.
Various guidelines and risk indices have optimized cardiac risk stratification, and the emphasis has shifted to reducing perioperative risk. This review is an update on invasive (CABG/PCI) and noninvasive (medical therapy with beta-blockers, alpha-agonists, and statins) strategies to reduce cardiac risk for noncardiac surgery and the controversies surrounding their use.
Cohn
Steven L
SL
State University of New York-Downstate, Division of General Internal Medicine, Brooklyn, New York 11203, USA. steven.cohn@downstate.edu
Auerbach
Andrew D
AD
D018663:Adrenergic Agents / Q000627:therapeutic use; D015906:Angioplasty, Balloon, Coronary; D001026:Coronary Artery Bypass; D006334:Heart Function Tests; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D009203:Myocardial Infarction / Q000517:prevention & control*; D011183:Postoperative Complications / Q000517:prevention & control*; D017410:Practice Guidelines as Topic; D011300:Preoperative Care; D018570:Risk Assessment
D018663:Adrenergic Agents; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors